TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02056379

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: The subjects will receive a 5 ml normal saline inhalation right after extubation and will be re-evaluated in 5 to 10 minutes. The ones who develop upper airway obstruction and stridor with a Downes-Raphaelly score of 2 or higher will receive 0.5 ml/kg of inhaled epinephrine 1:1000 diluted to a final volume of 5 ml with a maximum dose of 2.5 ml in children up to 4 years and 5 ml in children with 5 years and above, as recommended by the American Academy of Pediatrics. The subjects who do not show an improvement after the epinephrine treatment will then be randomized to receive 2 mg of inhaled budesonide and 3 ml of IV normal saline. If there is an improvement the following maintenance therapy will be instituted for 48 hs and the subjects will receive 2 mg of budesonide q12hs and 3 ml of IV NS q6hs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: The subjects will receive a 5 ml normal saline inhalation right after extubation and will be re-evaluated in 5 to 10 minutes. The ones who develop upper airway obstruction and stridor with a Downes-Raphaelly score of 2 or higher will receive 0.5 ml/kg of inhaled epinephrine 1:1000 diluted to a final volume of 5 ml with a maximum dose of 2.5 ml in children up to 4 years and 5 ml in children with 5 years and above, as recommended by the American Academy of Pediatrics. The subjects who do not show an improvement after the epinephrine treatment will then be randomized to receive 8 ml of inhaled normal saline and 0.6 mg/kg of IV dexamethasone. The dexamethasone group will receive 8 ml of inhaled NS q12hs and 0.15 mg/kg/dose of dexamethasone q6hs.
Study: NCT04036526

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine GamLPV
Description: live intranasal vaccine for whooping cough prevention

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine GamLPV
Description: live intranasal vaccine for whooping cough prevention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT01974011

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Performing dorsal penile nerve block (DPNB)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Performing dorsal penile nerve block (DPNB)
Study: NCT04578184

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Corneal epithelial thickness measurements
Description: Corneal epithelial thickness measurements using two optical coherence tomography devices in healthy and keratoconus corneas.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Corneal epithelial thickness measurements
Description: Corneal epithelial thickness measurements using two optical coherence tomography devices in healthy and keratoconus corneas.
Study: NCT00344500

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Weight Loss Program
Description: Patients randomized to the behavioral weight loss program (Lifestyle Balance Program) will do the following: -Meet with their psychiatrist and a nutritionist who will go over diet recommendations with the patient~* Be given a 7% weight loss goal~* Be assisted in obtaining a 500 calorie reduction per day~* Exercise for at least 30 min/day, at least 5 days a week~* Maintain weekly food and exercise diaries~* Be quizzed on their knowledge of healthy eating habits and nutrition
Study: NCT02207491

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol maleate Ophthalmic Solution 0.5% BID
Description: 1 drop BID, AM/PM, OU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-13324 Ophthalmic Solution 0.02%
Description: 1 drop once daily (QD), PM, OU

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 drop QD, AM, OU
Study: NCT04417153

Intervention type: BEHAVIORAL
Intervention: Mindfulness Based Intervention
Description: The mindfulness-based intervention consists of either four (MF) or eight (MBSR) 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion). Participants will be provided handouts for the information covered during these talks and discussions.These can be done either face to face or online.

Intervention type: BEHAVIORAL
Intervention: Mindfulness Based Intervention
Description: The mindfulness-based intervention consists of either four (MF) or eight (MBSR) 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion). Participants will be provided handouts for the information covered during these talks and discussions.These can be done either face to face or online.

Intervention type: BEHAVIORAL
Intervention: Mindfulness Based Intervention
Description: The mindfulness-based intervention consists of either four (MF) or eight (MBSR) 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion). Participants will be provided handouts for the information covered during these talks and discussions.These can be done either face to face or online.
Study: NCT01267942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enhancin
Description: Intravenous Enhancin at induction at a dose of 25 mg/kg amoxycillin equivalent.~Oral dose of the same at the same dosage for the active comparator arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enhancin
Description: Intravenous Enhancin at induction at a dose of 25 mg/kg amoxycillin equivalent.~Oral dose of the same at the same dosage for the active comparator arm.
Study: NCT03515356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI-Walk Intervention
Description: Eight-week motivational enhancement therapy and home-based aerobic walking intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Education Pamphlet
Description: Physical activity education pamphlet only

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Education Pamphlet
Description: Physical activity education pamphlet only
Study: NCT01958983

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy Group Session
Study: NCT03267888

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given 200 mg IV.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Patients will receive radiotherapy (8 Gy/1 fx) to an extra-osseous site and/or any bony site containing myeloma deposit.
Study: NCT00417963

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carotid Artery Stenting
Description: placement of a bare metal stent at sites of stenosis in the carotid artery
Study: NCT00793169

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Serum levels were measured
Study: NCT00477646

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention Care Management
Description: Telephone support over 18 months to help women become screened for breast, cervical and colon cancer. Includes barriers assessment, patient education and motivation, provider recommendation letter, appointment reminder, and some scheduling of appointments.
Study: NCT00477152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyaluronidase (human recombinant)/rehydration fluid
Description: Single 150 U subcutaneous (SC) HYLENEX dose administered immediately prior to start of SC infusion of rehydration fluid. Additional 150 U HYLENEX dose to be administered prior to any additional fluid infusion beyond 24 hours.
Study: NCT00005949

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp100:209-217(210M) peptide vaccine
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01531517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Royal Jelly and Panthenol (PedyPhar® Ointment)
Description: the following will be done to each patient depending on the number of the visit:~1. Assessment of the patient for inclusion/exclusion criteria~2. Informed consent process~3. Medical history of the patient~4. Blood withdrawn for investigation~5. Drainage of the ulcer if there is a collection~6. Revascularization as needed and indicated by APSV done at visit 0.~7. Swab from the ulcer for culture and micro-organism count: on detailed visits only.~8. Debridement as needed.~9. Dressing:~   * Inspection and assessment of the ulcer~  * Irrigation using 500 ml of saline or as required.~  * Drying of the ulcer (leave to dry)~  * Spread a layer of 3 - 5 mm of PedyPhar on a dressing and then apply the dressing to the ulcer~  * Fix the dressing to the ulcer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panthenol Ointment
Description: the following will be done to each patient depending on the number of the visit:~1. Assessment of the patient for inclusion/exclusion criteria~2. Informed consent process~3. Medical history of the patient~4. Blood withdrawn for investigation~5. Drainage of the ulcer if there is a collection~6. Revascularization as needed and indicated by APSV done at visit 0.~7. Swab from the ulcer for culture and micro-organism count: on detailed visits only.~8. Debridement as needed.~9. Dressing:~   * Inspection and assessment of the ulcer~  * Irrigation using 500 ml of saline or as required.~  * Drying of the ulcer (leave to dry)~  * Spread a layer of 3 - 5 mm of Panthenol on a dressing and then apply the dressing to the ulcer~  * Fix the dressing to the ulcer
Study: NCT03126435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EndoTAG-1
Description: twice weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: once weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: once weekly
Study: NCT01231776

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: electronic acupuncture
Description: applying a stimula on neiguang and shenmen through electronic acupuncture

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: electronic acupuncture
Description: applying a stimula on neiguang and shenmen through electronic acupuncture

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: electronic acupuncture
Description: applying a stimula on neiguang and shenmen through electronic acupuncture
Study: NCT01181869

Intervention type: DEVICE
Intervention: oxygen
Description: oxygen therapy, ventilation for respiratory failure CPAP for sleep apnoea
Study: NCT00443586

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening plus Transportation
Description: Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening plus Transportation
Description: Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening, Transport, Prenatal Visits
Description: Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy.
Study: NCT01181869

Intervention type: DEVICE
Intervention: oxygen
Description: oxygen therapy, ventilation for respiratory failure CPAP for sleep apnoea

Intervention type: DEVICE
Intervention: oxygen
Description: oxygen therapy, ventilation for respiratory failure CPAP for sleep apnoea
Study: NCT03221842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1-esterase inhibitor
Description: C1-esterase inhibitor is a human plasma-derived lyophilised powder for reconstitution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Excipients of C1-INH plus albumin
Study: NCT01286077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Each cycle will consist of 5 weeks treatment. Subjects in the treatment group will receive: Velcade® 1.6 mg/m2 as an intravenous bolus injection on Days 1, 8, 15, and 22 of each cycle followed by a 13-day rest period (Days 23 to 35) Cycle will be repeated on Day 36. Subjects in the treatment group will receive up to 4 treatment cycles, unless they experience either unacceptable toxicity or if the subject requests to withdraw from the study.
Study: NCT00590343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vatalanib
Description: Subjects who meet all inclusion and exclusion criteria will receive an initial dose of PTK787/ZK222584 1,250mg once daily, and subjects will remain on the scheduled doses of Sandostatin LAR 30mg every 4 weeks.
Study: NCT02156778

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Extended Standard Care (Stroke Card)
Description: Standard Care plus~extended training with access to weekly educational lectures (education of patients and relatives), implementation of My Stroke Card containing (a) an adopted version of the 'post-stroke checklist' (ascertainment of post-stroke complications), (b) self-administered internet-based tools for risk factor monitoring and reinforcement of target level achievement, and (c) information and educational materials.~3-Mo outpatient appointment with standardized assessment of risk factors and screening for complications, health problems and residual deficits, estimation of the patient's demand for nursing services and support, guideline-conform secondary prevention with full achievement of target levels, assessment of patient adherence to drug prescriptions.~6-Mo and 9-Mo visits on the discretion of the study team in case of medical needs.~12-Mo clinical visit and outcome assessment.
Study: NCT03173157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Value Feedback Email
Description: a biweekly email to three house staff-run cardiology services at VUMC presenting the in-hospital charges and appropriate use of echocardiography. A weekly email will also be sent to the intervention services detailing their team's in-hospital charges for echocardiograms during the preceeding week.
Study: NCT00165763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil hydrochloride (Aricept)
Description: 5 mg donepezil HCl given once a day and increased to 10 mg per day if side effects, when present, are tolerated.
Study: NCT02156778

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Standard Care
Description: In-hospital training (education of patients, next of kin and caregivers on risk factor management and assessment, life style improvement, and compliance).~Complimentary provision of a book / information material dealing with patient and caregiver relevant aspects of stroke care.~Advise by a dietitian (general advise and individualized recommendations in patients with diabetes and obesity).~Standardized information materials (e.g. for OAK or NOAK therapy). Support for smoking cessation and weight reduction if necessary or requested. Detailed medical reports (doctor's letter for the general practitioner and patient) at discharge containing target levels for risk factor management.~AF detection at the Stroke Unit (1-5 day monitoring) and/or at the ward (24-hour ECG).~12-Mo clinical visit and outcome assessment.
Study: NCT00443586

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening, Transport, Prenatal Visits
Description: Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screen, Transport, Prenatal/Inf Visits
Description: Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy and 23 during the child's first two years of life.
Study: NCT03439969

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile Text Messages
Description: Dental inter-proximal control with floss holder and receiving 16 SMS during 4 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile Text Messages
Description: Dental inter-proximal control with floss holder and receiving 16 SMS during 4 months.
Study: NCT04701567

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Description: Advanced multiparametric MRI techniques to diagnose hepatic and pancreatic disease

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Description: Advanced multiparametric MRI techniques to diagnose hepatic and pancreatic disease
Study: NCT03439969

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra Oral Camera
Description: SPT - Appointment with Intra-Oral Camera~* Examination and diagnosis (15 min) using Intra-oral camera.~* Motivation, discussion about desired outcomes and treatment needs (using Intra-oral camera) followed by instrumentation (scaling, polishing) (30 min).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra Oral Camera
Description: SPT - Appointment with Intra-Oral Camera~* Examination and diagnosis (15 min) using Intra-oral camera.~* Motivation, discussion about desired outcomes and treatment needs (using Intra-oral camera) followed by instrumentation (scaling, polishing) (30 min).
Study: NCT02276612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: 150/150/200/10 mg fixed-dose combination (FDC) tablet administered orally once daily with food
Study: NCT02260284

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yaotong points acupuncture
Description: Patients receive the treatments of Yaotong points penetration
Study: NCT01737853

Intervention type: DRUG
Intervention: Ganforti
Description: Enrolled patients will be visiting their clinical site at month 2 and month 3, after starting the study medication; at the end of the third month of treatment, a cross-over maneuver will be indicated; all patients will undergo a follow-up scheme similar to the first period of the study (at month 5 and month 6)

Intervention type: DRUG
Intervention: Krytantek
Description: Enrolled patients will be visiting their clinical site at month 2 and month 3, after starting the study medication; at the end of the third month of treatment, a cross-over maneuver will be indicated; all patients will undergo a follow-up scheme similar to the first period of the study (at month 5 and month 6)
Study: NCT03582891

Intervention type: DEVICE
Group type: OTHER
Intervention: Summit RC+S for Motor
Description: Using the RC+S pulse generator, investigators will measure cortical biomarkers of hyper and hypokinesia in Parkinson's and dystonia patients to develop an adaptive algorithm which adjusts the level of deep brain stimulation needed based upon the patient's physiology.

Intervention type: DEVICE
Group type: OTHER
Intervention: Summit RC+S for Motor
Description: Using the RC+S pulse generator, investigators will measure cortical biomarkers of hyper and hypokinesia in Parkinson's and dystonia patients to develop an adaptive algorithm which adjusts the level of deep brain stimulation needed based upon the patient's physiology.

Intervention type: DEVICE
Group type: OTHER
Intervention: Summit RC+S for Motor
Description: Using the RC+S pulse generator, investigators will measure cortical biomarkers of hyper and hypokinesia in Parkinson's and dystonia patients to develop an adaptive algorithm which adjusts the level of deep brain stimulation needed based upon the patient's physiology.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 8-week pilot trial of Closed-loop vs. Open-loop Stimulation
Description: These patients will participate in an 8 week clinical trial of open loop versus adaptive mode (4 weeks for each mode (interleaved), with the order counterbalanced across subjects ).
Study: NCT00191191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m2
Description: 500 mg/m2, intravenous (IV), every 21 days, one year from registration date

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed 1000 mg/m2
Description: 1000 mg/m2, intravenous (IV), every 21 days, one year from registration date
Study: NCT00912938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Intravenous zoledronic acid 4mg over a minimum of 15 minutes in at least 100mls of calcium free infusion solution (0.9% sodium chloride or 5% glucose solution) every 4 weeks.
Study: NCT02260284

Intervention type: OTHER
Group type: OTHER
Intervention: the usual care
Description: participants received no study-related care-just the care, if any, that they and their physicians chose: mostly massage and physical therapy visits and continued use of medications (mostly nonsteroidal anti-inflammatory drugs (NSAIDS))

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standardized acupuncture
Description: Patients were given to the standardized acupuncture groups. This prescription included six acupuncture points that are commonly applied for the treatment of CLBP (Bladder 23-bilateral, Bladder 40-bilateral, and Kidney 3-bilateral) on the low back and lower leg.
Study: NCT04212299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Northwestern University Flexible Sub-Ischial Suction Socket (NU-FlexSIS)
Description: The sub-ischial socket includes a firm, compressive, preferably cylindrical, fabric-covered silicone liner, a flexible inner socket, and a shorter rigid outer socket. The socket has proximal trim lines that do not impinge on the pelvis; they terminate distal to the ischial tuberosity and greater trochanter. For the NU-FlexSIS Socket, passive suction suspension is achieved using a one way valve and a liner with an internal seal.~Since the prosthetic socket is a custom-made device, it is considered Class I exempt by the Food and Drug Administration (FDA).